Duopharma Biotech

What Duopharma Biotech does

Duopharma Biotech Berhad is a Kuala Lumpur-headquartered, publicly listed (Bursa Malaysia: DBB) Malaysian pharmaceutical company organized into three operating segments: Consumer Healthcare (OTC brands CHAMPS, FLAVETTES, PROVITON, Uphamol, Eyeglo, Iroro, Dermoplex), Classic Pharmaceuticals (a portfolio of over 300 generic drugs across cardiovascular, respiratory, dermatology, neurology, anti-infectives and alimentary therapeutic classes), and Specialty Pharmaceuticals (biosimilars including Insugen recombinant human insulin, Basalog One insulin glargine, oncology biosimilars Kytron and Zuhera, and renal products Unihepa, Ranofer, and Haemosol). The company operates three GMP-certified manufacturing facilities (Klang, Bandar Baru Bangi, and Shah Alam), including the HAPI plant - Malaysia's only EU GMP-certified oncology manufacturing facility - and Malaysia's first biologic pre-filled syringe line. Its technology differentiator is a 'Halal Built-In, Not Tested For' manufacturing principle integrated since 1998, making it the first company globally to obtain JAKIM Halal certification for biologics, prescription medicines (2017), cancer treatments (2022), and biosimilars for renal therapy (2025).

Duopharma generates revenue through transaction-fee sales across three channels: (1) direct supply to the Malaysian Ministry of Health via wholly-owned subsidiaries Duopharma (M) Sendirian Berhad and Duopharma Marketing Sdn Bhd under multi-year tender contracts and the Approved Products Purchase List (APPL); (2) private sector sales of generics, biosimilars, and consumer healthcare to hospitals, clinics, pharmacies and retail chains (Watsons, Guardian); and (3) export sales through wholly-owned subsidiaries in Singapore, Indonesia (PT Duopharma Healthcare Indonesia, established 2023), and the Philippines. Pricing is predominantly quote-based via government tenders (e.g., three-year human insulin contract worth MYR 155.27 million) supplemented by retail-channel consumer product pricing. The company's primary strategic partnership with Biocon Sdn Bhd (since 2016) anchors its insulin business, having supplied over 120 million insulin cartridges to more than 450,000 patients.

Customers are concentrated in the public healthcare vertical (Malaysian Ministry of Health purchasing 100+ products under RM684.15 million of contract value through December 2026), supplemented by private hospitals and clinics, individual consumers via retail/OTC channels (including the dbhealth2go.com e-commerce platform), and regional importers in ASEAN markets. As a Government-linked Corporation that emerged from a 2017 demerger from Chemical Company of Malaysia Berhad, Duopharma plays a strategically important role in Malaysia's pharmaceutical self-reliance agenda. The company employs 875+ people, reported FY2025 revenue of RM931.69 million (+14.5% YoY) and Profit After Tax of RM87.46 million (+39.6% YoY), and in May 2026 held its 25th Annual General Meeting.

Name

Duopharma Biotech

Legal name

Duopharma Biotech Berhad

Website

https://duopharmabiotech.com

Company type

Public

Founded year

2000

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Duopharma Biotech Berhad is a Malaysian publicly-listed pharmaceutical company that manufactures generic drugs, biosimilars including insulin and oncology products, and halal-certified consumer healthcare brands for the Ministry of Health Malaysia, private healthcare providers, retail consumers, and ASEAN export markets.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD)

akta.pro secondary industries

Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Nephrology & Urology Pharmaceuticals (HLAIAAAM)

Keywords

• Generic pharmaceuticals
• Biosimilar manufacturing
• Halal pharmaceuticals
• Consumer healthcare products
• Prescription medicines

Headquarters

HQ city

Selangor

HQ country

Malaysia

HQ region

Asia

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Public Sector Pharmaceutical Sales: Supply of pharmaceutical and non-pharmaceutical products to Malaysian Government healthcare facilities under Ministry of Health contracts and Approved Products Purchase List (APPL). Includes insulin products via Biocon partnership.
2. Private Sector Sales: Sales of generic drugs, biosimilars, and consumer healthcare products to private hospitals, clinics, and pharmacies.
3. Export/International Sales: Regional operations in ASEAN markets including Singapore, Indonesia, Philippines with growing market penetration for generics, biosimilars, and consumer healthcare products.
4. Consumer Healthcare Products: Over-the-counter products including vitamins, supplements, analgesics, eyecare, antacids and skincare sold through pharmacies, retail stores, and e-commerce platform dbhealth2go.com.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

Duopharma Biotech Berhad researches, develops, manufactures, and commercializes more than 300 generic pharmaceutical products spanning cardiovascular, diabetes, oncology, renal, respiratory, dermatology and anti-infective therapeutic areas. The company also markets a portfolio of consumer healthcare brands (CHAMPS, FLAVETTES, PROVITON, Uphamol, Eyeglo, Naturalle, Iroro, Dermoplex) and biosimilars including Insugen (recombinant human insulin), Basalog One (insulin glargine), Insupen Pro pen devices, and the world-first halal-certified erythropoietin biosimilar for chronic renal failure.

Product overview

Duopharma Biotech operates as a Malaysian pharmaceutical company organized into three core business segments: (1) Consumer Healthcare marketing OTC brands including CHAMPS, FLAVETTES, PROVITON, Uphamol, Eyeglo, Naturalle, Iroro, and Dermoplex across vitamins/supplements, analgesics, eyecare, and skincare categories; (2) Classic Pharmaceuticals manufacturing and distributing over 300 generic drugs across cardiovascular, respiratory, neurology, anti-infectives, dermatology and other therapeutic classes; and (3) Specialty Pharmaceuticals focusing on biosimilars including Insugen (insulin), Basalog One (insulin glargine), oncology products (Kytron, Zuhera), renal products (Unihepa, Ranofer, Haemosol), and medical devices. The company is also a pioneer in Halal pharmaceuticals with JAKIM-certified products. In FY2025, the company expanded its Consumer Healthcare portfolio with CHAMPS Nutribar, FLAVETTES MsRange, and PROVITON STR energy gels.

Differentiator

Problem solved

Functional benefit

Brands

• CHAMPS: Vitamin C supplement brand for children
• FLAVETTES
• PROVITON
• UPHAMOL
• Omesec
• Prelica
• Eyeglo
• Naturalle
• Iroro

Products and services

• CHAMPS Nutribar Vitamin C-added healthy snack bar for children, part of the CHAMPS consumer healthcare brand launched in FY2025.
• FLAVETTES MsRange Powdered food supplement for beauty and wellness in women, launched in FY2025 as part of the FLAVETTES brand diversification.
• PROVITON STR Energy gels for revitalization and endurance in sports, launched in FY2025 under the PROVITON consumer healthcare brand.
• Insugen Recombinant human insulin biosimilar (Insugen-R, Insugen-N, Insugen 30/70) for diabetes treatment; supplied to Ministry of Health Malaysia under government contracts.
• Basalog One Long-acting insulin glargine biosimilar for diabetes management.
• Insupen Pro Reusable injectable pen device designed exclusively for use with the Insugen range of insulins.
• Halal Erythropoietin Biosimilar First halal-certified biosimilar erythropoietin product for treatment of anaemia associated with chronic renal failure in haemodialysis and predialysis patients, JAKIM-certified in 2025.
• Kytron Oncology biosimilar product for cancer treatment.
• Zuhera Oncology biosimilar product for cancer treatment.
• Unihepa Hepatology and renal specialty pharmaceutical product.
• Ranofer Renal specialty pharmaceutical product for chronic kidney disease management.
• Haemosol Renal specialty pharmaceutical product for haemodialysis use.
• Classic Pharmaceuticals Portfolio (300+ Generic Drugs) Over 300 generic drugs across therapeutic classes including cardiovascular, dermatology, hormones, respiratory, sensory and nervous system, musculo-skeletal, anti-infectives, and alimentary tract. Products include Vascor, Covasc, Prelica, Omesec, and Zynomax distributed in domestic and international markets.
• CHAMPS Children's vitamin C supplement brand sold in effervescent tablet form; award-winning consumer healthcare brand recognized as Most Voted Kid's Supplement at Guardian Awards.
• FLAVETTES Vitamin and supplement brand including effervescent vitamin C with glutathione, chewable vitamin C, and nutriskincare products for beauty and wellness.
• PROVITON Vitamin and supplement brand including multivitamins, mineral supplements and sports-focused offerings under the PROVITON family.
• Uphamol Paracetamol-based analgesic (pain relief) consumer brand; recognized with Gold award in Health Category at Putra Aria Brand Awards.
• Eyeglo Eye care product brand including eye moist drops, distributed through pharmacy and retail channels.
• Naturalle Supplement brand including garlic supplement and other natural health products.
• Iroro Hair growth treatment product (Iroro Nutreatment) targeting post-natal hair loss; winner of Best Post-Natal Hair Loss Treatment at Parents Choice Awards 2024.
• Dermoplex Skincare product line under Duopharma Biotech's consumer healthcare portfolio.

Quantifiable outcome

• Supplied over 120 million insulin cartridges to over 450,000 patients since 2016
• +4 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Biocon Sdn. Bhd.coreStrategic or Co-development Partner · 24 June 2026Long-standing strategic partnership since 2016 for insulin supply to Malaysian Ministry of Health. Biocon's Malaysian subsidiary supplies short-acting recombinant human insulin, insulin glargine, and insulin aspart for distribution through Duopharma's wholly-owned subsidiaries. Partnership has supplied over 120 million insulin cartridges to over 450,000 patients in Malaysia's public healthcare system. Biocon's integrated insulin manufacturing facility in Johor (largest in Asia) anchors the partnership.
• Alryxo Biotherapeutics Inc (formerly AZTherapies Inc)minorStrategic or Co-development PartnerBoston-based biopharmaceutical company developing novel small molecules and biologic therapies for neurodegenerative disease progression. Duopharma invested to gain low-cost entry to access marketing and manufacturing rights for a novel product for Alzheimer's Disease.
• Naluri HidupminorStrategic or Co-development PartnerLocal pioneer in digital therapeutics with proprietary Naluri application - digital health platform combining behavioural science, data science and digital design for holistic health management. Investment aligns with company's strategy to integrate digital health into Specialty and Consumer Healthcare businesses.
• SCM LifescienceminorStrategic or Co-development PartnerKorean stem cell firm invested in for diversification into biotherapeutics and high-value niche products. Includes SCM Lifescience's portfolio company Colmmune with immuno-oncology global cell therapy facility in the US.
• Centre for Affordable Diagnostics & Therapeutics LimitedminorStrategic or Co-development PartnerMoU signed to repurpose anti-malarial drug artesunate for cancer therapy and other applications.
• PAMOJA Therapeutics BVminorStrategic or Co-development PartnerMoU signed to repurpose anti-malarial drug artesunate for cancer therapy and other applications.
• Universiti Kebangsaan MalaysiaminorStrategic or Co-development PartnerPartnership to elevate Halal standards in healthcare. Co-hosted Halal Pharmaceutical Symposium 2024 with Faculty of Pharmacy. Collaboration on research and development for halal pharmaceuticals.
• Pangen Biotech IncminorStrategic or Co-development PartnerSouth Korean partner for Epoetin Alfa biosimilar development. First Malaysian pharmaceutical company to embark on Phase 3 clinical trial for an Epoetin Alfa biosimilar in collaboration with Pangen Biotech Inc in 2014.
• Department of Islamic Development Malaysia (JAKIM)coreOthersRegulatory body for halal certification in Malaysia. Duopharma Biotech received halal certification from JAKIM for multiple products including first prescription medicines (2017), first cancer treatment (2022), and biosimilar erythropoietin for chronic kidney disease (2025).

Scale indicators12 records

Recent moves16 records

Expansion highlights7 records

Direct peers

• Pharmaniaga Berhad: Malaysian pharmaceutical company and direct competitor to Duopharma for Ministry of Health generic drug and insulin tenders. Operates a similar dual model of government contract manufacturing and consumer healthcare brands, and is one of the few Malaysian-listed pharma peers competing for the same APPL/MOH contract pool.
• Biocon Limited: Indian biopharmaceutical company and Duopharma's core strategic partner for insulin supply since 2016. Directly comparable as a global biosimilars player with recombinant human insulin, insulin glargine, and insulin aspart — the same molecules Duopharma distributes in Malaysia — making it the closest functional peer despite the partner/customer dynamic.
• Hovid Berhad: Malaysian generic pharmaceutical manufacturer with a similar product portfolio across cardiovascular, anti-infectives, and consumer healthcare. Competes with Duopharma in the same Malaysian generics, OTC, and government supply markets.

Regional players

• Kalbe Farma: Indonesia's largest pharmaceutical company with a broad generic, consumer healthcare, and biosimilars portfolio. Comparable business model (generic manufacturing + consumer brands) and serves as the dominant Southeast Asian pharma player Duopharma's Indonesian subsidiary will compete against.
• Julphar (Gulf Pharmaceutical Industries): Middle East-based pharmaceutical manufacturer with strong halal positioning and biosimilars/generics portfolio. Directly comparable to Duopharma on halal pharmaceutical manufacturing and emerging-market distribution, though focused on MENA rather than ASEAN.
• Dexa Medica: Indonesian pharmaceutical company with branded generics and consumer healthcare. Comparable as a Southeast Asian specialty/generics competitor with deep local market presence that Duopharma's Indonesian representative office must compete with for market entry.

Broad incumbents

• Aspen Pharmacare Holdings: South African-headquartered global specialty and generics pharmaceutical group with a broad emerging-market portfolio. Comparable as a Southern Hemisphere / emerging-market pharma champion with branded generics, specialty, and consumer healthcare segments across multiple therapeutic areas.
• Dr. Reddy's Laboratories: Indian-headquartered global pharmaceutical company with leading positions in generics, biosimilars, and proprietary products. Comparable on biosimilars (including insulin analogs and oncology) and global emerging-market commercialization, though materially larger scale.
• Cipla Limited: Indian-headquartered global pharmaceutical manufacturer with strong respiratory, cardiovascular, and biosimilars presence. Comparable on emerging-market generic and specialty pharma model, with significant ASEAN and African distribution footprint.

Others

• Chemical Company of Malaysia Berhad (CCMB): Former parent of Duopharma Biotech prior to the 2017 demerger. CCMB retains related chemical/pharmaceutical operations and is a useful reference for understanding Duopharma's history and prior corporate scope, though no longer a direct operating peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCD1kcFqXh4QM1P6qh7QOazA
• Instagraminstagram.com/flavettes/?hl=en

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Subsidiaries10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Duopharma Biotech